Şeker, MesutAydın, DinçerBilici, AhmetYavuzer, DilekÖzgün Geçer, MelinÖzçelik, MelikeAydın, ÖzhanAliustaoğlu, Mehmet10.07.20192019-07-1010.07.20192019-07-102017Şeker, M., Aydın, D., Bilici, A., Yavuzer, D., Özgün Geçer, M., Özçelik, M. ... Aliustaoğlu,M. (2017). Correlation of caveolin-1 expression with prognosis in patients with gastric cancer after gastrectomy. Oncology Research and Treatment, 40(4), 185-190. https://dx.doi.org/10.1159/0004566202296-52702296-5262https://dx.doi.org/10.1159/000456620https://hdl.handle.net/20.500.12511/3590WOS: 000398884100003PubMed ID: 28365694Background: Upregulation of caveolin-1 (Cav-1) expression is correlated with histopathological grade and poor prognosis in several human cancers. However, in gastric cancer, its clinical utility as a useful prognostic molecular marker remains unclear. Methods: The prognostic importance of Cav-1 expression was retrospectively analyzed by immunohistochemistry in 148 patients with gastric cancer who had undergone radical gastrectomy. Results: Cav-1 expression was positive in 23 (15.5%) patients and negative in 125 (84.5%) patients. Tumor location, tumor grade, lymph node involvement, pT stage, pTNM stage, and the presence of recurrence were found to be significantly associated with Cav-1 expression. The median disease-free survival (DFS) of patients with negative Cav-1 expression was significantly better than that of patients with positive Cav-1 expression (not reached vs. 10.2 months, p < 0.001). Moreover, patients with positive Cav-1 expression had a worse median overall survival (OS) compared to patients with negative Cav-1 expression (14.2 vs. 40.3 months, p = 0.004). In the multivariate analysis, Cav-1 expression (positive vs. negative) was an independent prognostic factor for DFS (p < 0.001, hazard ratio (HR) 2.58) and OS (p = 0.031, HR 1.87), as was lymph node metastasis. Conclusion: Our results suggest that positive Cav-1 expression is associated with progression and poor prognosis in gastric cancer patients after radical gastrectomy. Targeting Cav-1 would be a potential option for future gastric cancer treatment.eninfo:eu-repo/semantics/embargoedAccessCaveolin-1PrognosisGastric CancerImmunohistochemistryArticle40418519010.1159/000456620Q4Q3